Enobia Pharma

Quebec City, Canada Founded: 1997 • Age: 29 yrs Acquired By Alexion
Therapies for genetic metabolic bone disorders are developed.
Annual revenue - Latest available
Total funding $138.5M 5 rounds
Employees - Tracked headcount
Investors 8 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Enobia Pharma

Enobia Pharma is a company based in Quebec City (Canada) founded in 1997 was acquired by Alexion in December 2011. Enobia Pharma has raised $138.52 million across 5 funding rounds from investors including Alexion, Desjardins and Orbimed. Enobia Pharma operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Horizon Therapeutics and Corcept, among others.

  • Headquarter Quebec City, Canada
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $138.52 M (USD)

    in 5 rounds

  • Latest Funding Round
    $20 M (USD), Series D

    Aug 23, 2011

  • Investors
    Alexion

    & 7 more

  • Employee Count
    Employee Count
  • Acquired by
    Alexion

    (Dec 28, 2011)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Enobia Pharma

Enobia Pharma has successfully raised a total of $138.52M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $20 million completed in August 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series D — $20.0M
  • First Round

    (18 Jan 2005)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2011 Amount Series D - Enobia Pharma Valuation

investors

Apr, 2011 Amount Series D - Enobia Pharma Valuation

investors

Aug, 2009 Amount Series C - Enobia Pharma Valuation Lothian Partners

Investors in Enobia Pharma

Enobia Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Desjardins and Orbimed.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
CTI Capital is engaged in securities brokerage and venture capital investment.
Founded Year Domain Location
-
Founded Year Domain Location

Investments & Acquisitions by Enobia Pharma

Investments

Financial Statements - Enobia Pharma

Enobia Pharma Comparisons

+
Add Comparison
Available on Premium

Competitors of Enobia Pharma

Enobia Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Horizon Therapeutics and Corcept, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Developer of small-molecule drugs
domain founded_year HQ Location
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Developer of cortisol modulators for the treatment of various diseases
domain founded_year HQ Location
Cell therapy for diabetes is developed from stem cells.

Latest news on Enobia Pharma

Frequently Asked Questions about Enobia Pharma

Enobia Pharma was founded in 1997 and raised its 1st funding round 8 years after it was founded.

Enobia Pharma is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.

Enobia Pharma is a funded company, having raised a total of $138.52M across 5 funding rounds to date. The company's 1st funding round was a Series C of $50M, raised on Jan 18, 2005.

Enobia Pharma was founded in 1997 in Quebec City, Canada, within the biotechnology sector. Focus is placed on creating treatments for severe genetic metabolic bone disorders lacking approved options. Operations involve research and development of therapeutic candidates. The primary product, ENB-0040, targets hypophosphatasia, which leads to skeletal deformities, muscle weakness, and damage to vital organs. Activities are centered in Canada.

Enobia Pharma's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.

Enobia Pharma has 8 investors. Key investors include Alexion, Desjardins, Orbimed, CTI Capital, and Lothian Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available